Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).

Giulia Baciarello,Rémy Delva,Gwenaelle Gravis,Youssef Tazi,Christine Theodore,Marine Gross-Goupil,Emmanuelle Bompas,Florence Joly,Tifenn Lharidon,Thierry Nguyen Tan Hon,Philippe Barthélémy,Stéphane Culine,Jean François Berdah,M. Deblock,Philippe Beuzeboc,Aude Flechon,Caroline Cheneau,Geraldine Martineau,Isabelle Borget,Karim Fizazi

Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).

2019

5017Background: Docetaxel and cabazitaxel represent now the standard of care in men with mCRPC with similar efficacy reported in metastatic first-line setting in the FIRSTANA phase 3 trial. We asse...

Keywords:

Oncology
Cabazitaxel
Castrate-resistant prostate cancer
Pathology
Docetaxel
Chemotherapy
Medicine
Internal medicine
first line chemotherapy
standard of care
patient preference
Physical therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations